News
Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.
Published: 4th March 2022
3P Biopharmaceuticals, a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO), is part of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.
Read more
3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director
Published: 11th February 2022
3P Biopharmaceuticals appoints a new member to the management team with the incorporation of Ricardo Izquierdo as Quality Director.
Read more
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2
Published: 26th November 2022
Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more
Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE
Published: 17th November 2022
Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021
Read more
3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA
Published: 29th September 2021
The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more
3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology
Published: 17th August 2021
3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
Read more
3P Biopharmaceuticals receives FDA approval
Published: 5th July 2021
The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized
Read more
3P Biopharmaceuticals reinforces its commitment to female talent with its participation in the programme ‘Lidera en femenino-STEM’
Published: 29th June 2021
The Head of Quality Assurance & Qualified Person at 3P Biopharmaceuticals, Susana Santesteban, has attended ‘Lidera en femenino-STEM’, a course that aims to help promote the career advancement of STEM women.
Read more
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours
Published: 20th June 2021
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for cGMP manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.
Read more